Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute effects of trimetazidine evaluated by exercise testing.

P Sellier1, P Audouin, B Payen

  • 1Department of Cardiology, Hôpital Broussais, Paris, France.

European Journal of Clinical Pharmacology
|January 1, 1987
PubMed
Summary

A single 60 mg dose of trimetazidine significantly improved exercise capacity and reduced ischemia in angina pectoris patients. These benefits occurred without affecting heart rate or blood vessels, demonstrating efficacy with a single dose.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A myotropic AAV vector combined with skeletal muscle <i>cis</i>-regulatory elements improve glycogen clearance in mouse models of Pompe disease.

Molecular therapy. Methods & clinical development·2025
Same author

Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics.

The Journal of antimicrobial chemotherapy·2024
Same author

Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa<sup>-/-</sup> mice.

Journal of inherited metabolic disease·2023
Same author

Nursing Activities Score is increased in COVID-19 patients.

Intensive & critical care nursing·2020
Same author

Prospective study comparing the conventional and same-day strategies to diagnose pulmonary tuberculosis.

Medecine et maladies infectieuses·2019
Same author

Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?

HIV medicine·2018

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angina pectoris is a condition characterized by chest pain due to reduced blood flow to the heart.
  • Trimetazidine is a medication used to treat angina, typically administered chronically.
  • Previous studies recognized the benefits of chronic trimetazidine administration.

Purpose of the Study:

  • To evaluate the effects of a single 60 mg dose of trimetazidine on exercise capacity in patients with angina pectoris.
  • To determine if these beneficial effects align with those observed after chronic administration.

Main Methods:

  • Participants with angina pectoris received a single 60 mg dose of trimetazidine.
  • Exercise capacity was assessed by measuring exercise duration and total work performed.
  • Electrocardiogram (ECG) signs of ischemia were monitored.

Related Experiment Videos

Main Results:

  • A single 60 mg dose of trimetazidine increased exercise duration and total work performed.
  • ECG signs of ischemia showed improvement following the single dose.
  • No significant chronotropic (heart rate) or vasomotor (blood vessel) effects were detected.

Conclusions:

  • A single 60 mg dose of trimetazidine is effective in improving exercise capacity and reducing ischemia in angina pectoris.
  • These acute benefits are comparable to those seen with chronic trimetazidine regimens.
  • Trimetazidine offers a viable therapeutic option for angina management, even in single-dose administration.